{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:42:48Z","timestamp":1792662168576,"version":"4.5.0"},"reference-count":76,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>It is always a daunting task to treat urinary tract infection (UTI) as these\ninfections may be chronic or lead to complications and drug resistance. The bacteria form a biofilm,\nwhich results in the failure of the antibiotics. The common organisms include Escherichia\ncoli, Klebsiella, and Enterococcus. Gepotidacin is considered to be the first-in-class oral triazaacenaphthylene\nbacterial topoisomerase inhibitor (NBTI). Recently, it was approved by the FDA for\ntreating uncomplicated urinary tract infections in females aged 12 years and older. This literature\nreview aims to evaluate current evidence on the clinical efficacy, safety, dosing, and resistance\nprofile of gepotidacin in the treatment of urinary tract infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A literature search was conducted using PubMed, Cochrane Library, Google Scholar,\nand Scopus to identify original and review articles published from 1990 to the present. The search\nwas refined using the keywords: Gepotidacin, drug, DNA gyrase inhibitor, antibiotic, broad spectrum,\nand UTI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In this mini-review, we discuss the recently approved drug gepotidacin and highlight its\naction in UTIs. The drug acts on the enzyme targets such as DNA gyrase and topoisomerase IV,\nthereby inhibiting the DNA replication of bacteria. Interestingly, the drug acts on both Gram-positive\nand Gram-negative bacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The efficacy of gepotidacin against common uropathogens makes it a popular choice\nfor treating urinary tract and urogonorrheal infections. The drug is well-tolerated with fewer side\neffects and is hence considered to be safe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Considering the cases of antibiotic resistance and novel mechanisms of action, the\nbroad-spectrum action of gepotidacin may be beneficial in treating UTIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501427795260418200529","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:08:51Z","timestamp":1779725331000},"page":"889-900","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Urinary Tract Infections with Gepotidacin: The Promising\nAntibiotic"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-5300","authenticated-orcid":true,"given":"Nazik","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Human and Clinical Anatomy, College of Medicine and Health Sciences, Sultan Qaboos University,Muscat123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-4087","authenticated-orcid":true,"given":"Yamamh","family":"Al-Jubori","sequence":"additional","affiliation":[{"name":"Department of Human and Clinical Anatomy, College of Medicine and Health Sciences, Sultan Qaboos University,Muscat123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5817-5677","authenticated-orcid":true,"given":"Rawan","family":"Al-Busaidi","sequence":"additional","affiliation":[{"name":"Department of Human and Clinical Anatomy, College of Medicine and Health Sciences, Sultan Qaboos University,Muscat123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8302-7257","authenticated-orcid":true,"given":"Srijit","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Human and Clinical Anatomy, College of Medicine and Health Sciences, Sultan Qaboos University,Muscat123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","volume":"28","author":"Foxman B.","year":"2014","unstructured":"Foxman B.; Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am  2014,28(1),1-13","journal-title":"Infect Dis Clin North Am"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"Flores-Mireles A.L.","year":"2015","unstructured":"Flores-Mireles A.L.; Walker J.N.; Caparon M.; Hultgren S.J.; Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol  2015,13(5),269-284","journal-title":"Nat Rev Microbiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"Gupta K.","year":"2011","unstructured":"Gupta K.; Hooton T.M.; Naber K.G.; Wullt B.; Colgan R.; Miller L.G.; Moran G.J.; Nicolle L.E.; Raz R.; Schaeffer A.J.; Soper D.E.; International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis Infectious Diseases Society of America 2011,52(5),e103-e120","journal-title":"Clin Infect Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1756287219832172","DOI":"10.1177\/1756287219832172","volume":"11","author":"Medina M.","year":"2019","unstructured":"Medina M.; Castillo-Pino E.; An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol  2019,11,1756287219832172","journal-title":"Ther Adv Urol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.idc.2013.10.002","volume":"28","author":"Gupta K.","year":"2014","unstructured":"Gupta K.; Bhadelia N.; Management of urinary tract infections from multidrug-resistant organisms. Infect Dis Clin North Am  2014,28(1),49-59","journal-title":"Infect Dis Clin North Am"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/tropicalmed7030042","volume":"7","author":"Mohamed A.H.","year":"2022","unstructured":"Mohamed A.H.; Sheikh Omar N.M.; Osman M.M.; Mohamud H.A.; Eraslan A.; Gur M.; Antimicrobial resistance and predisposing factors associated with catheter-associated UTI caused by uropathogens exhibiting multidrug-resistant patterns: A 3-year retrospective study at a tertiary hospital in mogadishu, somalia. Trop Med Infect Dis  2022,7(3),42","journal-title":"Trop Med Infect Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/acem.14545","volume":"29","author":"Faine B.A.","year":"2022","unstructured":"Faine B.A.; Rech M.A.; Vakkalanka P.; Gross A.; Brown C.; Harding S.J.; Slocum G.; Zimmerman D.; Zepeski A.; Rewitzer S.; Howington G.T.; Campbell M.; Dawson J.; Treu C.N.; Nelson L.; Jones M.; Flack T.; Porter B.; Sarangarm P.; Mattson A.E.; Bailey A.; Kelly G.; Talan D.A.; High prevalence of fluoroquinolone-resistant UTI among US emergency department patients diagnosed with urinary tract infection, 2018\u20132020. Acad Emerg Med  2022,29(9),1096-1105","journal-title":"Acad Emerg Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature09197","volume":"466","author":"Bax B.D.","year":"2010","unstructured":"Bax B.D.; Chan P.F.; Eggleston D.S.; Fosberry A.; Gentry D.R.; Gorrec F.; Giordano I.; Hann M.M.; Hennessy A.; Hibbs M.; Huang J.; Jones E.; Jones J.; Brown K.K.; Lewis C.J.; May E.W.; Saunders M.R.; Singh O.; Spitzfaden C.E.; Shen C.; Shillings A.; Theobald A.J.; Wohlkonig A.; Pearson N.D.; Gwynn M.N.; Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature  2010,466(7309),935-940","journal-title":"Nature"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1128\/AAC.02820-15","volume":"60","author":"Biedenbach D.J.","year":"2016","unstructured":"Biedenbach D.J.; Bouchillon S.K.; Hackel M.; Miller L.A.; Scangarella-Oman N.E.; Jakielaszek C.; Sahm D.F.; In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother  2016,60(3),1918-1923","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","volume":"379","author":"Taylor S.N.","year":"2018","unstructured":"Taylor S.N.; Marrazzo J.; Batteiger B.E.; Hook E.W.; Se\u00f1a A.C.; Long J.; Wierzbicki M.R.; Kwak H.; Johnson S.M.; Lawrence K.; Mueller J.; Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med  2018,379(19),1835-1845","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s15010-007-6180-2","volume":"35","author":"Laupland K.B.","year":"2007","unstructured":"Laupland K.B.; Ross T.; Pitout J.D.D.; Church D.L.; Gregson D.B.; Community-onset urinary tract infections: A population-based assessment. Infection  2007,35(3),150-153","journal-title":"Infection"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"l525","DOI":"10.1136\/bmj.l525","volume":"364","author":"Gharbi M.","year":"2019","unstructured":"Gharbi M.; Drysdale J.H.; Lishman H.; Goudie R.; Molokhia M.; Johnson A.P.; Holmes A.H.; Aylin P.; Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: Population based cohort study. BMJ  2019,364,l525","journal-title":"BMJ"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3390\/jcm10112332","volume":"10","author":"Palacios-Ce\u00f1a D.","year":"2021","unstructured":"Palacios-Ce\u00f1a D.; Florencio L.L.; Hern\u00e1ndez-Barrera V.; Fernandez-de-las-Pe\u00f1as C.; de Miguel-Diez J.; Mart\u00ednez-Hern\u00e1ndez D.; Carabantes-Alarc\u00f3n D.; Jimenez-Garc\u00eda R.; Lopez-de-Andres A.; Lopez-Herranz M.; Trends in incidence and outcomes of hospitalizations for urinary tract infection among older people in spain (2001\u20132018). J Clin Med  2021,10(11),2332","journal-title":"J Clin Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/ahe.13.38","volume":"9","author":"Rowe T.A.","year":"2013","unstructured":"Rowe T.A.; Juthani-Mehta M.; Urinary tract infection in older adults. Aging Health  2013,9(5),519-528","journal-title":"Aging Health"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e2039","DOI":"10.1002\/hsr2.2039","volume":"7","author":"Hossain M.J.","year":"2024","unstructured":"Hossain M.J.; Azad A.K.; Shahid M.S.B.; Shahjahan M.; Ferdous J.; Prevalence, antibiotic resistance pattern for bacteriuria from patients with urinary tract infections. Health Sci Rep  2024,7(4),e2039","journal-title":"Health Sci Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s12879-023-08578-1","volume":"23","author":"Almutawif Y.A.","year":"2023","unstructured":"Almutawif Y.A.; Eid H.M.A.; Prevalence and antimicrobial susceptibility pattern of bacterial uropathogens among adult patients in madinah, saudi arabia. BMC Infect Dis  2023,23(1),582","journal-title":"BMC Infect Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0022-5347(01)65154-1","volume":"157","author":"Yamamoto S.","year":"1997","unstructured":"Yamamoto S.; Tsukamoto T.; Terai A.; Kurazono H.; Takeda Y.; Yoshida O.; Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. J Urol  1997,157(3),1127-1129","journal-title":"J Urol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.juro.2011.09.035","volume":"187","author":"Bitsori M.","year":"2012","unstructured":"Bitsori M.; Maraki S.; Koukouraki S.; Galanakis E.; Pseudomonas aeruginosa urinary tract infection in children: Risk factors and outcomes. J Urol  2012,187(1),260-264","journal-title":"J Urol"},{"key":"ref=19","author":"Wein A.J.","year":"2016","unstructured":"Wein A.J.; Kavoussi L.R.; Partin A.W.; Peters C.A.;  Campbell-Walsh urology  2016","journal-title":"Campbell-Walsh urology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12875-022-01816-6","volume":"23","author":"Schmiemann G.","year":"2022","unstructured":"Schmiemann G.; Hoffmann F.; Hamprecht A.; Jobski K.; Patterns and trends of antibacterial treatment in patients with urinary tract infections, 2015\u20132019: An analysis of health insurance data. BMC Prim Care  2022,23(1),204","journal-title":"BMC Prim Care"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/717094","volume":"2015","author":"Hsiao C.Y.","year":"2015","unstructured":"Hsiao C.Y.; Yang H.Y.; Chang C.H.; Lin H.L.; Wu C.Y.; Hsiao M.C.; Hung P.H.; Liu S.H.; Weng C.H.; Lee C.C.; Yen T.H.; Chen Y.C.; Wu T.C.; Risk factors for development of septic shock in patients with urinary tract infection. BioMed Res Int  2015,2015,1-7","journal-title":"BioMed Res Int"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.emc.2018.06.003","volume":"36","author":"Long B.","year":"2018","unstructured":"Long B.; Koyfman A.; The emergency department diagnosis and management of urinary tract infection. Emerg Med Clin North Am  2018,36(4),685-710","journal-title":"Emerg Med Clin North Am"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.11622\/smedj.2016153","volume":"57","author":"Tan C.W.","year":"2016","unstructured":"Tan C.W.; Chlebicki M.P.; Urinary tract infections in adults. Singapore Med J  2016,57(9),485-490","journal-title":"Singapore Med J"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.emc.2019.07.007","volume":"37","author":"Dubbs S.B.","year":"2019","unstructured":"Dubbs S.B.; Sommerkamp S.K.; Evaluation and management of urinary tract infection in the emergency department. Emerg Med Clin North Am  2019,37(4),707-723","journal-title":"Emerg Med Clin North Am"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.4065\/74.7.730","volume":"74","author":"Smilack J.D.","year":"1999","unstructured":"Smilack J.D.; Trimethoprim-sulfamethoxazole. Mayo Clin Proc  1999,74(7),730-734","journal-title":"Mayo Clin Proc"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0002-9343(02)01053-7","volume":"113","author":"Stamm W.E.","year":"2002","unstructured":"Stamm W.E.; Scientific and clinical challenges in the management of urinary tract infections. Am J Med  2002,113(1),1-4","journal-title":"Am J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1517\/14656566.1.1.109","volume":"1","author":"Norrby S.R.","year":"1999","unstructured":"Norrby S.R.; Levofloxacin. Expert Opin Pharmacother  1999,1(1),109-119","journal-title":"Expert Opin Pharmacother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","volume":"18","author":"Raz R.","year":"2012","unstructured":"Raz R.; Fosfomycin: An old\u2014new antibiotic. Clin Microbiol Infect  2012,18(1),4-7","journal-title":"Clin Microbiol Infect"},{"key":"ref=29","author":"Evans J.","year":"2025","unstructured":"Evans J.; Hanoodi M.; Wittler M.;  Amoxicillin Clavulanate StatPearls  2025","journal-title":"Amoxicillin Clavulanate StatPearls"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12894-020-00605-6","volume":"20","author":"Koguchi D.","year":"2020","unstructured":"Koguchi D.; Murakami Y.; Ikeda M.; Dobashi M.; Ishii J.; Cefaclor as a first-line treatment for acute uncomplicated cystitis: a retrospective single-center study. BMC Urol  2020,20(1),38","journal-title":"BMC Urol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1179\/joc.1999.11.3.163","volume":"11","author":"Brumfitt W.","year":"1999","unstructured":"Brumfitt W.; Hamilton-Miller J.M.T.; Cefaclor into the millennium. J Chemother  1999,11(3),163-178","journal-title":"J Chemother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003495-199100423-00009","volume":"42","author":"Cox C.E.","year":"1991","unstructured":"Cox C.E.; Graveline J.F.; Luongo J.M.; Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections. Drugs  1991,42,41-50","journal-title":"Drugs"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2165\/00003495-199652010-00009","volume":"52","author":"Perry C.M.","year":"1996","unstructured":"Perry C.M.; Brogden R.N.; Cefuroxime axetil. Drugs  1996,52(1),125-158","journal-title":"Drugs"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/10600280241288554","volume":"59","author":"Burchette J.E.","year":"2025","unstructured":"Burchette J.E.; Covert K.; Tu P.; White B.P.; Chastain D.B.; Cluck D.B.; Pivmecillinam for uncomplicated acute cystitis: A contemporary review. Ann Pharmacother  2025,59(8),743-757","journal-title":"Ann Pharmacother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/bmjebm-2024-112920","volume":"30","author":"Kristensen L.H.","year":"2025","unstructured":"Kristensen L.H.; Winther R.; Colding-J\u00f8rgensen J.T.; Potteg\u00e5rd A.; Nielsen H.; Bodilsen J.; Diagnostic accuracy of dipsticks for urinary tract infections in acutely hospitalised patients: A prospective population-based observational cohort study. BMJ Evid Based Med  2025,30(1),36-44","journal-title":"BMJ Evid Based Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e59069","DOI":"10.7759\/cureus.59069","volume":"16","author":"Almuhanna H.S.","year":"2024","unstructured":"Almuhanna H.S.; Alhojelan A.M.; Al Rusayni Y.A.; Almohanna M.A.; AlDhalea H.M.; Aljulajil A.A.; Comparison between urine dipstick and microscopic examination urinalysis with urine culture to evaluate the sensitivity and specificity for each in diagnosing urinary tract infection in qassim region, saudi arabia. Cureus  2024,16(4),e59069","journal-title":"Cureus"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/00325481.2019.1679540","volume":"132","author":"Kavuru V.","year":"2020","unstructured":"Kavuru V.; Vu T.; Karageorge L.; Choudhury D.; Senger R.; Robertson J.; Dipstick analysis of urine chemistry: Benefits and limitations of dry chemistry-based assays. Postgrad Med  2020,132(3),225-233","journal-title":"Postgrad Med"},{"key":"ref=38","first-page":"27","volume":"106","author":"Hitzeman N.","year":"2022","unstructured":"Hitzeman N.; Greer D.; Carpio E.; Office-based urinalysis: A comprehensive review. Am Fam Physician  2022,106(1),27-35B","journal-title":"Am Fam Physician"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10157-019-01812-8","volume":"24","author":"Akagawa Y.","year":"2020","unstructured":"Akagawa Y.; Kimata T.; Akagawa S.; Fujishiro S.; Kato S.; Yamanouchi S.; Tsuji S.; Kino M.; Kaneko K.; Optimal bacterial colony counts for the diagnosis of upper urinary tract infections in infants. Clin Exp Nephrol  2020,24(3),253-258","journal-title":"Clin Exp Nephrol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1053\/j.ajkd.2015.11.011","volume":"67","author":"Becker G.J.","year":"2016","unstructured":"Becker G.J.; Garigali G.; Fogazzi G.B.; Advances in urine microscopy. Am J Kidney Dis  2016,67(6),954-964","journal-title":"Am J Kidney Dis"},{"key":"ref=41","author":"Sinawe H.","year":"2025","unstructured":"Sinawe H.; Casadesus D.;  Urine Culture  2025","journal-title":"Urine Culture"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","volume":"86","author":"Kranz J.","year":"2024","unstructured":"Kranz J.; Bartoletti R.; Bruy\u00e8re F.; Cai T.; Geerlings S.; K\u00f6ves B.; Schubert S.; Pilatz A.; Veeratterapillay R.; Wagenlehner F.M.E.; Bausch K.; Devlies W.; Horv\u00e1th J.; Leitner L.; Mantica G.; Mezei T.; Smith E.J.; Bonkat G.; European association of urology guidelines on urological infections: Summary of the 2024 guidelines. Eur Urol  2024,86(1),27-41","journal-title":"Eur Urol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2014.303","volume":"311","author":"Mody L.","year":"2014","unstructured":"Mody L.; Juthani-Mehta M.; Urinary tract infections in older women: A clinical review. JAMA  2014,311(8),844-854","journal-title":"JAMA"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1128\/CMR.1.3.268","volume":"1","author":"Pezzlo M.","year":"1988","unstructured":"Pezzlo M.; Detection of urinary tract infections by rapid methods. Clin Microbiol Rev  1988,1(3),268-280","journal-title":"Clin Microbiol Rev"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/978-3-319-67066-9_25","author":"Harri P.A.","year":"2018","unstructured":"Harri P.A.; Mittal P.K.; Moreno C.C.; Acute urinary tract conditions in adults: Evidence-based emergency imaging. Evidence-Based Emergency Imaging  2018,383-397","journal-title":"Evidence-Based Emergency Imaging"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00345-004-0414-z","volume":"22","author":"Bjerklund Johansen T.E.","year":"2004","unstructured":"Bjerklund Johansen T.E.; The role of imaging in urinary tract infections. World J Urol  2004,22(5),392-398","journal-title":"World J Urol"},{"key":"ref=47","author":"eastham J.H.","year":"2025","unstructured":"eastham J.H.; Patel P.; Phenazopyridine. StatPearls  2025","journal-title":"StatPearls"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"CD010745","DOI":"10.1002\/14651858.CD010745.pub2","volume":"2016","author":"O\u2019Kane D.B.","year":"2016","unstructured":"O\u2019Kane D.B.; Dave S.K.; Gore N.; Patel F.; Hoffmann T.C.; Trill J.L.; Del Mar C.B.; Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women. Cochrane Libr  2016,2016(4),CD010745","journal-title":"Cochrane Libr"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"CD001321","DOI":"10.1002\/14651858.CD001321.pub6","volume":"2023","author":"Williams G.","year":"2023","unstructured":"Williams G.; Hahn D.; Stephens J.H.; Craig J.C.; Hodson E.M.; Cranberries for preventing urinary tract infections. Cochrane Libr  2023,2023(4),CD001321","journal-title":"Cochrane Libr"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/archinternmed.2012.777","volume":"172","author":"Beerepoot M.A.J.","year":"2012","unstructured":"Beerepoot M.A.J.; ter Riet G.; Nys S.; van der Wal W.M.; de Borgie C.A.; de Reijke T.M.; Prins J.M.; Koeijers J.; Verbon A.; Stobberingh E.; Geerlings S.E.; Lactobacilli vs antibiotics to prevent urinary tract infections: A randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med  2012,172(9),704-712","journal-title":"Arch Intern Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/antibiotics11060751","volume":"11","author":"Kresken M.","year":"2022","unstructured":"Kresken M.; Pfeifer Y.; Wagenlehner F.; Werner G.; Wohlfarth E.; Resistance to mecillinam and nine other antibiotics for oral use in escherichia coli isolated from urine specimens of primary care patients in germany, 2019\/20. Antibiotics On Behalf Of Study Group 'Antimicrobial Resistance' Of The Paul Ehrlich Society For Infection Therapy 2022,11(6),751","journal-title":"Antibiotics"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12919-025-00333-5","volume":"19","author":"Gupta K.","year":"2025","unstructured":"Gupta K.; Wagenlehner F.; Wilcox M.; Advani S.D.; Bilsen M.; Bonkat G.; Cant\u00f3n R.; Geerlings S.; Grabein B.; Horcajada J.P.; Kushner P.; Narayanan N.; Scheetz M.; Urinary tract infection in adults: Gaps in current guidelines \u2013 opinions from an international multidisciplinary panel and relevance to clinical practice. BMC Proc  2025,19(S16),18","journal-title":"BMC Proc"},{"key":"ref=53","year":"2023","unstructured":"CKS via NICE is only available to eligible users within the UK. National Institute for Health and Care Excellence (NICE) Available from:  https:\/\/cks.nice.org.uk\/topics\/urinary-tract-infection-lower-women2023"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","volume":"74","author":"Tamma P.D.","year":"2022","unstructured":"Tamma P.D.; Aitken S.L.; Bonomo R.A.; Mathers A.J.; van Duin D.; Clancy C.J.; Infectious diseases society of america guidance on the treatment of AmpC \u03b2-Lactamase\u2013producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections. Clin Infect Dis  2022,74(12),2089-2114","journal-title":"Clin Infect Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","author":"Tamma P.D.","year":"2024","unstructured":"Tamma P.D.; Heil E.L.; Justo J.A.; Mathers A.J.; Satlin M.J.; Bonomo R.A.; Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis  2024(Aug),ciae403","journal-title":"Clin Infect Dis"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12879-015-1153-z","volume":"15","author":"Han S.B.","year":"2015","unstructured":"Han S.B.; Lee S.C.; Lee S.Y.; Jeong D.C.; Kang J.H.; Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis  2015,15(1),414","journal-title":"BMC Infect Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","volume":"403","author":"Wagenlehner F.","year":"2024","unstructured":"Wagenlehner F.; Perry C.R.; Hooton T.M.; Scangarella-Oman N.E.; Millns H.; Powell M.; Jarvis E.; Dennison J.; Sheets A.; Butler D.; Breton J.; Janmohamed S.; Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): Two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet  2024,403(10428),741-755","journal-title":"Lancet"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5582\/ddt.2025.01028","volume":"19","author":"Hu S.","year":"2025","unstructured":"Hu S.; Yu H.; Gao J.; Gepotidacin: The first-in-class triazaacenaphthylene antibiotic approved for the treatment of uncomplicated urinary tract infections. Drug Discov Ther  2025,19(2),129-130","journal-title":"Drug Discov Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e02095-16","DOI":"10.1128\/AAC.02095-16","volume":"61","author":"O\u2019Riordan W.","year":"2017","unstructured":"O\u2019Riordan W.; Tiffany C.; Scangarella-Oman N.; Perry C.; Hossain M.; Ashton T.; Dumont E.; Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother  2017,61(6),e02095-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","volume":"5","author":"Gibson E.G.","year":"2019","unstructured":"Gibson E.G.; Bax B.; Chan P.F.; Osheroff N.; Mechanistic and structural basis for the actions of the antibacterial gepotidacin against staphylococcus aureus gyrase. ACS Infect Dis  2019,5(4),570-581","journal-title":"ACS Infect Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"11688","DOI":"10.3390\/ijms252111688","volume":"25","author":"Morgan H.","year":"2024","unstructured":"Morgan H.; Nicholls R.A.; Warren A.J.; Ward S.E.; Evans G.; Long F.; Murshudov G.N.; Duman R.; Bax B.D.; How do gepotidacin and zoliflodacin stabilize dna cleavage complexes with bacterial type IIA topoisomerases? 1. Experimental definition of metal binding sites. Int J Mol Sci  2024,25(21),11688","journal-title":"Int J Mol Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","volume":"22","author":"Redgrave L.S.","year":"2014","unstructured":"Redgrave L.S.; Sutton S.B.; Webber M.A.; Piddock L.J.V.; Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol  2014,22(8),438-445","journal-title":"Trends Microbiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/nyas.12830","volume":"1354","author":"Hooper D.C.","year":"2015","unstructured":"Hooper D.C.; Jacoby G.A.; Mechanisms of drug resistance: Quinolone resistance. Ann N Y Acad Sci  2015,1354(1),12-31","journal-title":"Ann N Y Acad Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e00468-17","DOI":"10.1128\/AAC.00468-17","volume":"61","author":"Flamm R.K.","year":"2017","unstructured":"Flamm R.K.; Farrell D.J.; Rhomberg P.R.; Scangarella-Oman N.E.; Sader H.S.; Gepotidacin (GSK2140944) in vitro activity against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother  2017,61(7),e00468-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e00199-20","DOI":"10.1128\/AAC.00199-20","volume":"64","author":"Overcash J.S.","year":"2020","unstructured":"Overcash J.S.; Tiffany C.A.; Scangarella-Oman N.E.; Perry C.R.; Tao Y.; Hossain M.; Barth A.; Dumont E.F.; Phase 2a pharmacokinetic, safety, and exploratory efficacy evaluation of oral gepotidacin (GSK2140944) in female participants with uncomplicated urinary tract infection (acute uncomplicated cystitis). Antimicrob Agents Chemother  2020,64(7),e00199-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/sextrans-2022-055518","volume":"99","author":"Scangarella-Oman N.E.","year":"2023","unstructured":"Scangarella-Oman N.E.; Hossain M.; Perry C.R.; Tiffany C.; Powell M.; Swift B.; Dumont E.F.; Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea. Sex Transm Infect  2023,99(1),64-69","journal-title":"Sex Transm Infect"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jama.2022.1246","volume":"327","author":"Hazra A.","year":"2022","unstructured":"Hazra A.; Collison M.W.; Davis A.M.; CDC sexually transmitted infections treatment guidelines, 2021. JAMA  2022,327(9),870-871","journal-title":"JAMA"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/cid\/ciy145","volume":"67","author":"Taylor S.N.","year":"2018","unstructured":"Taylor S.N.; Morris D.H.; Avery A.K.; Workowski K.A.; Batteiger B.E.; Tiffany C.A.; Perry C.R.; Raychaudhuri A.; Scangarella-Oman N.E.; Hossain M.; Dumont E.F.; Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: A phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis  2018,67(4),504-512","journal-title":"Clin Infect Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e01639-24","DOI":"10.1128\/aac.01639-24","volume":"69","author":"Scangarella-Oman N.E.","year":"2025","unstructured":"Scangarella-Oman N.E.; Butler D.L.; Breton J.; Brown D.; Kasapidis C.; Sheets A.J.; Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes\/epidemiological clones, in females with uncomplicated urinary tract infections: Results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrob Agents Chemother  2025,69(10),e01639-24","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"e01640-24","DOI":"10.1128\/aac.01640-24","volume":"69","author":"Scangarella-Oman N.E.","year":"2025","unstructured":"Scangarella-Oman N.E.; Butler D.L.; Breton J.; Brown D.; Kasapidis C.; Millns H.; Huang C.; Perry C.R.; Sheets A.J.; Dennison J.; Janmohamed S.; Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: Results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrob Agents Chemother  2025,69(10),e01640-24","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e00296-25","DOI":"10.1128\/aac.00296-25","volume":"69","author":"Hackel M.A.","year":"2025","unstructured":"Hackel M.A.; Karlowsky J.A.; Sahm D.F.; West J.M.; Scangarella-Oman N.E.; In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis, and Staphylococcus saprophyticus. Antimicrob Agents Chemother  2025,69(6),e00296-25","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s40121-022-00706-9","volume":"11","author":"Perry C.","year":"2022","unstructured":"Perry C.; Hossain M.; Powell M.; Raychaudhuri A.; Scangarella-Oman N.; Tiffany C.; Xu S.; Dumont E.; Janmohamed S.; Design of two phase III, randomized, multicenter studies comparing gepotidacin with nitrofurantoin for the treatment of uncomplicated urinary tract infection in female participants. Infect Dis Ther  2022,11(6),2297-2310","journal-title":"Infect Dis Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e00483-22","DOI":"10.1128\/aac.00483-22","volume":"66","author":"Fishman C.","year":"2022","unstructured":"Fishman C.; Caverly Rae J.M.; Posobiec L.M.; Laffan S.B.; Lerman S.A.; Pearson N.; Janmohamed S.; Dumont E.; Nunn-Floyd D.; Stanislaus D.J.; Novel bacterial topoisomerase inhibitor gepotidacin demonstrates absence of fluoroquinolone-like arthropathy in juvenile rats. Antimicrob Agents Chemother  2022,66(11),e00483-22","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e01492-21","DOI":"10.1128\/aac.01492-21","volume":"66","author":"Scangarella-Oman N.E.","year":"2022","unstructured":"Scangarella-Oman N.E.; Hossain M.; Hoover J.L.; Perry C.R.; Tiffany C.; Barth A.; Dumont E.F.; Dose selection for phase III clinical evaluation of gepotidacin (GSK2140944) in the treatment of uncomplicated urinary tract infections. Antimicrob Agents Chemother  2022,66(3),e01492-21","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12866-021-02245-8","volume":"21","author":"Nuzzo A.","year":"2021","unstructured":"Nuzzo A.; Van Horn S.; Traini C.; Perry C.R.; Dumont E.F.; Scangarella-Oman N.E.; Gardiner D.F.; Brown J.R.; Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944). BMC Microbiol  2021,21(1),181","journal-title":"BMC Microbiol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"102829","DOI":"10.1016\/j.jiac.2025.102829","volume":"32","author":"Yamamoto S.","year":"2026","unstructured":"Yamamoto S.; Fujii K.; Kayama Y.; Nimura A.; Maenaka T.; Ramirez M.; Banerjee R.; Scangarella-Oman N.E.; Mozzicato S.; Ura S.; Konishi T.; Kawahara M.; Hashimoto J.; Sekiguchi Y.; Umeyama T.; Hayashi M.; Sugimoto K.; Iwata S.; Mori M.; Tanahashi Y.; Suyama K.; Manabe F.; Kamijo T.; Nanri M.; Hayami Y.; Kamei M.; Kusuyama H.; Igarashi H.; Kameoka H.; Sagiyama K.; Ura S.; Takashima H.; Huang T.; Kayama S.; Muromiya Y.; Nakamura K.; Ogishima T.; Oral gepotidacin for the treatment of uncomplicated urinary tract infection in Japanese female patients: A randomized, active reference, double-blind, double-dummy, Phase 3 trial (EAGLE-J). J Infect Chemother  2026,32(1),102829","journal-title":"J Infect Chemother"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501427795260418200529","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/253460\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501427795260418200529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:25:03Z","timestamp":1792661103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/253460\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":76,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501427795260418200529","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}